WEE1 kinase inhibition reverses G2/M cell cycle checkpoint activation to sensitize cancer cells to immunotherapy

Replication Catastrophe: When a Checkpoint Fails because of Exhaustion

(2017) Luis Toledo et al.   MOLECULAR CELL

Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells

(2017) Paul E. Clavijo et al.   Oncotarget

SMAC Mimetic Birinapant plus Radiation Eradicates Human Head and Neck Cancers with Genomic Amplifications of Cell Death Genes FADD and BIRC2

(2016) Danielle F. Eytan et al.   CANCER RESEARCH

Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor- B Signaling for Cancer Treatment

(2016) K. P. Zeligs et al.   CLINICAL CANCER RESEARCH

Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies

(2016) Sujay Shah et al.   HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress

(2016) Kyle C. Cuneo et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors

(2016) Suzanne Leijen et al.   JOURNAL OF CLINICAL ONCOLOGY

Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer

(2016) Ruth J. Davis et al.   ORAL ONCOLOGY

Combined inhibition of Wee1 and Chk1 gives synergistic DNA damage in S-phase due to distinct regulation of CDK activity and CDC45 loading

(2016) Sissel Hauge et al.   Oncotarget

Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade

(2016) E. Moore et al.   Cancer Immunology Research

Eradication of Large Solid Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation

(2015) M. Leisegang et al.   CLINICAL CANCER RESEARCH

Cross-dressing: an alternative mechanism for antigen presentation

(2015) Stefania Campana et al.   IMMUNOLOGY LETTERS

Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors

(2015) Khanh Do et al.   JOURNAL OF CLINICAL ONCOLOGY

WEE1 Inhibition Alleviates Resistance to Immune Attack of Tumor Cells Undergoing Epithelial-Mesenchymal Transition

(2014) D. H. Hamilton et al.   CANCER RESEARCH

A Surprising Cross-Species Conservation in the Genomic Landscape of Mouse and Human Oral Cancer Identifies a Transcriptional Signature Predicting Metastatic Disease

(2014) M. D. Onken et al.   CLINICAL CANCER RESEARCH

Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence

(2014) A. A. Osman et al.   MOLECULAR CANCER THERAPEUTICS

Adjuvant Combination and Antigen Targeting as a Strategy to Induce Polyfunctional and High-Avidity T-Cell Responses against Poorly Immunogenic Tumors

(2011) F. Aranda et al.   CANCER RESEARCH

ERK1/2 Regulation of CD44 Modulates Oral Cancer Aggressiveness

(2011) N. P. Judd et al.   CANCER RESEARCH

WEE1 Kinase Targeting Combined with DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe

(2011) P. C. De Witt Hamer et al.   CLINICAL CANCER RESEARCH

WEE1 Inhibition Sensitizes Basal Breast Cancer Cells to TRAIL-Induced Apoptosis

(2011) S. V. Garimella et al.   MOLECULAR CANCER RESEARCH

Mitotic catastrophe: a mechanism for avoiding genomic instability

(2011) Ilio Vitale et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents

(2009) H. Hirai et al.   MOLECULAR CANCER THERAPEUTICS

IFN-γ– and TNF-dependent bystander eradication of antigen-loss variants in established mouse cancers

(2008) Bin Zhang et al.   JOURNAL OF CLINICAL INVESTIGATION